CA2453198A1 - Quantification et production d'exosomes immunosuppresseurs - Google Patents

Quantification et production d'exosomes immunosuppresseurs Download PDF

Info

Publication number
CA2453198A1
CA2453198A1 CA 2453198 CA2453198A CA2453198A1 CA 2453198 A1 CA2453198 A1 CA 2453198A1 CA 2453198 CA2453198 CA 2453198 CA 2453198 A CA2453198 A CA 2453198A CA 2453198 A1 CA2453198 A1 CA 2453198A1
Authority
CA
Canada
Prior art keywords
exosomes
antibody
exosome
cells
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2453198
Other languages
English (en)
Inventor
Wei-Ping Min
Thomas Emanuel Ichim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 2453198 priority Critical patent/CA2453198A1/fr
Publication of CA2453198A1 publication Critical patent/CA2453198A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
CA 2453198 2004-01-07 2004-01-07 Quantification et production d'exosomes immunosuppresseurs Abandoned CA2453198A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2453198 CA2453198A1 (fr) 2004-01-07 2004-01-07 Quantification et production d'exosomes immunosuppresseurs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2453198 CA2453198A1 (fr) 2004-01-07 2004-01-07 Quantification et production d'exosomes immunosuppresseurs

Publications (1)

Publication Number Publication Date
CA2453198A1 true CA2453198A1 (fr) 2005-07-07

Family

ID=34716035

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2453198 Abandoned CA2453198A1 (fr) 2004-01-07 2004-01-07 Quantification et production d'exosomes immunosuppresseurs

Country Status (1)

Country Link
CA (1) CA2453198A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007088537A2 (fr) * 2006-01-31 2007-08-09 Medical Research Fund Of Tel Aviv Sourasky Medical Center Procédés et trousses pour la détection précoce du cancer ou d'une prédisposition au cancer
WO2007103572A3 (fr) * 2006-03-09 2008-09-12 Aethlon Medical Inc Enlèvement extracorporel de particules microvésiculaires
WO2009092386A2 (fr) 2008-01-25 2009-07-30 Hansabiomed Oü Nouveau procédé de mesure et de caractérisation de microvésicules dans des liquides organiques humain
WO2009100029A1 (fr) * 2008-02-01 2009-08-13 The General Hospital Corporation Utilisation de microvésicules dans le diagnostic, le pronostic et le traitement de maladies et d’affections médicales
GB2463401A (en) * 2008-11-12 2010-03-17 Caris Mpi Inc Diagnostic methods using exosomes
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US20170143812A1 (en) * 2015-11-20 2017-05-25 Therapeutic Solutions International, Inc. Exosome mediated innate and adaptive immune stimulation for treatment of cancer
CN106814187A (zh) * 2017-01-16 2017-06-09 杭州联川基因诊断技术有限公司 外周游离外泌体在制备液态活检肿瘤诊断试剂中的应用
US10022483B2 (en) 2003-01-17 2018-07-17 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
EP3299816A4 (fr) * 2015-05-20 2018-10-03 JSR Corporation Procédé de séparation, procédé de détection, procédé de mesure de signal, procédé de détermination de maladie, procédé d'évaluation de l'efficacité d'un médicament, kit, composition de liquide et diluant d'échantillon
US10407728B2 (en) 2009-09-09 2019-09-10 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
US10793914B2 (en) 2010-08-31 2020-10-06 The General Hospital Corporation Cancer-related biological materials in microvesicles
US10988755B2 (en) 2010-11-10 2021-04-27 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
US11155874B2 (en) 2009-09-09 2021-10-26 The General Hospital Corporation Use of microvesicles in analyzing mutations
CN114891723A (zh) * 2022-06-30 2022-08-12 北京三元食品股份有限公司 一种乳源外泌体及提取方法

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022483B2 (en) 2003-01-17 2018-07-17 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
WO2007088537A3 (fr) * 2006-01-31 2007-10-25 Medical Res Fund Of Tel Aviv S Procédés et trousses pour la détection précoce du cancer ou d'une prédisposition au cancer
US9394569B2 (en) 2006-01-31 2016-07-19 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and kits for early detection of cancer or predisposition thereto
WO2007088537A2 (fr) * 2006-01-31 2007-08-09 Medical Research Fund Of Tel Aviv Sourasky Medical Center Procédés et trousses pour la détection précoce du cancer ou d'une prédisposition au cancer
US8288172B2 (en) 2006-03-09 2012-10-16 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
WO2007103572A3 (fr) * 2006-03-09 2008-09-12 Aethlon Medical Inc Enlèvement extracorporel de particules microvésiculaires
US9364601B2 (en) 2006-03-09 2016-06-14 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
EP3517151A1 (fr) * 2006-03-09 2019-07-31 Aethlon Medical, Inc. Enlèvement extracorporel de particules microvésiculaires
US9707333B2 (en) 2006-03-09 2017-07-18 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
WO2009092386A2 (fr) 2008-01-25 2009-07-30 Hansabiomed Oü Nouveau procédé de mesure et de caractérisation de microvésicules dans des liquides organiques humain
CN102317778A (zh) * 2008-01-25 2012-01-11 汉萨生物医药公司 测定和表征人体液中微泡的新方法
WO2009092386A3 (fr) * 2008-01-25 2009-09-17 Hansabiomed Oü Nouveau procédé de mesure et de caractérisation de microvésicules dans des liquides organiques humain
RU2520741C2 (ru) * 2008-01-25 2014-06-27 Хансабиомед Ою Новый способ количественного определения и охарактеризования микровезикул в жидкостях организма человека
AU2009207927B2 (en) * 2008-01-25 2015-04-09 Exosomics S.p.A. A new method to measure and characterize microvesicles in the human body fluids
CN102317778B (zh) * 2008-01-25 2015-05-13 汉萨生物医药公司 测定和表征人体液中微泡的新方法
EP2604704B1 (fr) * 2008-02-01 2018-10-03 The General Hospital Corporation Utilisation de microvésicules pour le diagnostic et le pronostic de la tumeur cérébrale
WO2009100029A1 (fr) * 2008-02-01 2009-08-13 The General Hospital Corporation Utilisation de microvésicules dans le diagnostic, le pronostic et le traitement de maladies et d’affections médicales
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
GB2463401A (en) * 2008-11-12 2010-03-17 Caris Mpi Inc Diagnostic methods using exosomes
US11519036B2 (en) 2009-09-09 2022-12-06 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US11155874B2 (en) 2009-09-09 2021-10-26 The General Hospital Corporation Use of microvesicles in analyzing mutations
US10407728B2 (en) 2009-09-09 2019-09-10 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US10793914B2 (en) 2010-08-31 2020-10-06 The General Hospital Corporation Cancer-related biological materials in microvesicles
US10988755B2 (en) 2010-11-10 2021-04-27 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
EP3299816A4 (fr) * 2015-05-20 2018-10-03 JSR Corporation Procédé de séparation, procédé de détection, procédé de mesure de signal, procédé de détermination de maladie, procédé d'évaluation de l'efficacité d'un médicament, kit, composition de liquide et diluant d'échantillon
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
US20170143812A1 (en) * 2015-11-20 2017-05-25 Therapeutic Solutions International, Inc. Exosome mediated innate and adaptive immune stimulation for treatment of cancer
CN106814187B (zh) * 2017-01-16 2018-11-09 杭州联川基因诊断技术有限公司 外周游离外泌体在制备液态活检肿瘤诊断试剂中的应用
CN106814187A (zh) * 2017-01-16 2017-06-09 杭州联川基因诊断技术有限公司 外周游离外泌体在制备液态活检肿瘤诊断试剂中的应用
CN114891723A (zh) * 2022-06-30 2022-08-12 北京三元食品股份有限公司 一种乳源外泌体及提取方法

Similar Documents

Publication Publication Date Title
Pedroza-Gonzalez et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation
US11905529B2 (en) Method of enhancing persistence of adoptively infused T cells
CA2453198A1 (fr) Quantification et production d'exosomes immunosuppresseurs
Wong et al. IL-18–primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment
Rodrigues et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties
Brimnes et al. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma
Baur et al. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg
Wong et al. The role of CD200 in immunity to B cell lymphoma
Rodrigues et al. Tolerogenic IDO+ dendritic cells are induced by PD-1-expressing mast cells
US8097242B2 (en) Target CA125 peptides for cancer immunotherapy
EP2245142A2 (fr) Identification de lymphocytes cd8+ qui ont une expression élevée de cd161 (cd161hi) et/ou de il18r (alpha) (il18r (alpha)hi) et qui ont une capacité d'écoulement de médicament rapide
US20170000850A1 (en) Differentiation therapy with cd137 ligand agonists
JPWO2005094886A1 (ja) Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
Wu et al. Inhibition of iNKT cells by the HLA-G-ILT2 checkpoint and poor stimulation by HLA-G-expressing tolerogenic DC
Ogden et al. Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas
JP2022543026A (ja) Ｎｋ細胞を評価するためのシステム及び方法
Ghorbaninezhad et al. CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro
Figueroa‐Vega et al. Phenotypic analysis of IL‐10‐treated, monocyte‐derived dendritic cells in patients with systemic lupus erythematosus
Cui et al. CD80+ dendritic cell derived exosomes inhibit CD8+ T cells through down-regulating NLRP3 expression after liver transplantation
Gasparoto et al. Regulatory T cells in the actinic cheilitis
Radej et al. Immunomodelling characteristics of mature dendritic cells stimulated by colon cancer cells lysates
US11612644B2 (en) Cell population for use in treating cancer
US20070128670A1 (en) Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and use thereof
Clark et al. Monocytes immunoselected via the novel monocyte specific molecule, CD300e, differentiate into active migratory dendritic cells
Piapi Characterisation of CD3-enhanced gene-modified CD4+ T cells for cancer immunotherapy

Legal Events

Date Code Title Description
FZDE Dead